Midostaurin
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-MIDOSTAURIN |
|---|---|
| Type | Drug |
| Aliases | RydaptМідостаурин |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-AML DIS-MASTOCYTOSIS |
| Sources | SRC-NCCN-AML-2025 SRC-RATIFY-STONE-2017 |
Drug Facts
| Class | Multi-kinase inhibitor (FLT3, KIT, PDGFR, VEGFR, PKC) |
|---|---|
| Mechanism | Multi-targeted TKI; clinically used for FLT3-ITD/TKD AML (added to 7+3 induction + HiDAC consolidation) and advanced systemic mastocytosis (KIT D816V). |
| Typical dosing | AML FLT3+: 50 mg PO BID days 8-21 of each induction + consolidation cycle, then maintenance 50 mg BID for 12 cycles (RATIFY protocol). Take with food. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Standard FLT3-ITD/TKD AML 1L (RATIFY trial: improved OS vs placebo when added to 7+3 + HiDAC). Take with food to maximize bioavailability. Antiemetic prophylaxis essential. Not Ukraine-reimbursed — major access constraint; gilteritinib (single-agent r/r) and quizartinib also FLT3-active.
Used By
Regimens
REG-AML-7-3- 7+3 Induction (cytarabine + daunorubicin/idarubicin) ± midostaurinREG-MIDOSTAURIN-ADVSM-1L- Midostaurin monotherapy (advanced systemic mastocytosis, 1L alternative; D816V- or avapri...